RNA-seq of AML cells with MPI KO and FLT3 tyrosine kinase inhibition

·Released Feb. 27, 2023

Samples

Assays

References

Description

Molm13 AML cell line both control and MPI KO, treated with AC220 (quizartinib) and mannose at 24 and 72 hours after drug treatment. 2 reads and 2 repeats for each condition, 2 timepoints, 48 total files.

References

Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death.

Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Rattigan KM, Philippe C, Dembitz V, Magee AMS, Asby R, van de Lagemaat LN, Mapperley C, James SC, Prehn JHM, Tzelepis K, Rouault-Pierre K, Vassiliou GS, Kranc KR, Helgason GV, Huntly BJP, Gallipoli P.

Sample Attributes

Organism

Homo sapiens

Cell line

MOLM-13

Disease

acute myeloid leukemia

Developmental stage

adult

Organism part

blood

Genotype

MPI knockout, wild type genotype

Experiment Info

Accession

E-MTAB-11750

Type

RNA-seq of coding RNA

Organism

Homo sapiens, Homo sapiens

Released

Feb. 27, 2023

Submitter

Keith Woodley

External Links

ArrayExpress source

Analysis Services

RNA-seq of AML cells with MPI KO and FLT3 tyrosine kinase inhibition

Contact

WeChat Official Account